Cannabinol (CBN)
6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol
Overview
Cannabinol (CBN) belongs to Cannabinoids.
Effects
- Mildly psychoactive: far weaker than THC. Only large doses produce intoxication, and CBN alone typically produces little noticeable effect.
- Popularly sold for sleep/sedation, but controlled human evidence for a hypnotic effect of CBN alone is lacking.
- Sedation historically attributed to CBN more likely reflected residual THC in aged cannabis.
Dosing & duration
Not reported
Dose ranges
Duration
Chemical & Physical Properties
| Formula | C21H26O2 |
| Molar mass | 310.4 g/mol |
| State | Not reported |
| Melting point | 76–77 °C (NTP, 1992) |
| Boiling point | 185 °C at 0.05 mmHg (NTP, 1992) |
| Density | Not reported |
| Vapor pressure | Not reported |
| pKa | Not reported |
| LogP | 6.1 (predicted, XLogP3) |
| Solubility | Not reported |
| Refractive index | Not reported |
Identifiers & Synonyms
| CAS | 521-35-7 |
| CAS (enantiomer) | |
| PubChem CID | 2543 |
| InChIKey | VBGLYOIFKLUMQG-UHFFFAOYSA-N |
| InChI | InChI=1S/C21H26O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9-13,22H,5-8H2,1-4H3 |
| SMILES | CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O |
Synonyms
- CBN
- Cannabinol
Pharmacodynamics & Biochemistry
Cannabinol (CBN) is a mildly psychoactive phytocannabinoid that, uniquely among the major cannabinoids, is not made enzymatically by the plant but forms by oxidative degradation of THC on exposure to heat, light and oxygen, so it accumulates in aged or poorly stored cannabis. It is only weakly intoxicating: much larger doses than THC are needed to produce any psychoactive effect. At the cannabinoid receptors CBN is a low-affinity partial agonist. It binds CB1 several-fold (≈5–10×) more weakly than THC (CB1 Ki reported ≈200–560 nM), and unusually it binds CB2 with somewhat greater affinity than CB1, giving it a modest CB2 bias: the opposite of THC's CB1 preference. This weak CB1 agonism is why aged, CBN-rich cannabis is far less intoxicating than fresh material. CBN is widely marketed as a 'sleep cannabinoid', but this reputation is poorly supported. The idea traces to old observations that aged cannabis felt more sedating, yet that cannabis also still contained THC. A 2021 review (Corroon) concluded there is no good controlled human evidence that CBN alone is sedating, and that the historic sedation was more plausibly due to residual THC. CBN on its own appears to produce little systemic effect. Beyond the cannabinoid receptors CBN modulates several TRP channels (a TRPA1/ANKTM1 agonist and a low-affinity agonist at TRPV1–4) and blocks voltage-gated sodium channels (Nav1.7, Nav1.8): an emerging non-intoxicating analgesic interest. It is highly lipophilic and hepatically metabolised by CYP2C9 and CYP3A4. Its main metabolite 11-OH-CBN is reportedly about twice as potent as CBN. Human pharmacokinetic data are limited.
Biological targets
- CB1
- CB2
Binding & functional measurements
| Target | Measurement | Species |
|---|---|---|
| CB1 receptor | Ki 285 nM | Human |
| CB1 receptor | EC50 307 nM | Human |
| CB2 receptor | EC50 289 nM | Human |
| CB2 receptor | Ki 163 nM | Human |
Pharmacokinetics
| Bioavailability | Not well characterised, highly lipophilic with poor/variable oral absorption, like other cannabinoids |
| Tmax | Not reported |
| Half-life | Not established in humans |
| Vd | Not reported |
| Protein binding | Not reported |
| Metabolism | Hepatic, CYP2C9 & CYP3A4. Active metabolite 11-OH-CBN (~2× potency) |
| Excretion | Not reported |
Toxicology & Safety
Not reported
CBN is only mildly psychoactive and, in the limited human data available, appears well tolerated, but robust safety data are lacking, and most evidence comes from preclinical work or from THC-containing cannabis rather than CBN alone. Its popular reputation as a sleep aid is not established by controlled trials. Marketed CBN products (gummies, oils, 'nighttime' tinctures) are unregulated supplements of variable quality and content. Some are made by chemically converting CBD and may carry residual THC or synthesis by-products. No CBN product is an approved medicine.[3][2]
Legal Status
US: Not scheduled (contested). UK: Class B. DE: Not scheduled (contested)
Interactions & Contraindications
Drug interactions
Contraindications
No interactions or contraindications listed.
Usage & Context
- Sold as a mildly-/non-intoxicating cannabinoid supplement, heavily marketed for sleep, CBN gummies, oils and 'nighttime' tinctures, despite limited evidence.
- A subject of preclinical research for analgesic (Nav-channel), anti-inflammatory, appetite-stimulating and neuroprotective effects: none approved or confirmed in humans.
- Forms naturally as cannabis ages, and is used analytically as a marker of cannabis age/degradation.
Sources & Evidence
- PubChem: Cannabinol (CID 2543) — identifiers & computed properties
- Wikipedia: Cannabinol (formation, pharmacology, targets, metabolism & legal status) CC BY-SA 4.0
- Corroon J (2021). Cannabinol and Sleep: Separating Fact from Fiction. Cannabis Cannabinoid Res 6:366-371.
PMID 34468204 · doi:10.1089/can.2021.0006
- Felder CC, Joyce KE, Briley EM, et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-50.
PMID 7565624
- Ghovanloo MR, Effraim PR, Tyagi S, et al. (2024). Functionally-selective inhibition of threshold sodium currents and excitability in dorsal root ganglion neurons by cannabinol. Commun Biol 7:120.
PMID 38263462 · doi:10.1038/s42003-024-05781-x
- IUPHAR/BPS Guide to PHARMACOLOGY: cannabinol (ligand 740) — CB/TRPV2/Nav binding data CC BY-SA 4.0